Clinical Trial Search

Primary: Overall Tumor Response — 6; 0; 1; 26 participants

Primary: Change in Mean Weekly Morning Peak Expiratory Flow From Baseline to the End of the Trial — -3.93; -3.15; -24.63 L/min

Primary: Plaque Index — 2.63; 2.65; 1.23 Units on a scale — p=0.05

Primary: Pathologic Local Tumor Response — 8; 6; 11 Participants

Primary: Number of Subjects With Dose Limiting Toxicities (DLT) — 0; 0; 2 participants

Primary: Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 26 — 44.4; 73.3; 60.0; 55.6 Percentage of subjects

Primary: Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at Week 12 — 33.49 Meters

Primary: Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 34 — 66.7; 28.6; 42.9; 33.3 Percentage of subjects

Primary: Number of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST) — 35 participants

Primary: Percentage of Participants With an Overall Resonse — 8.2 percentage of participants

Primary: Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set) — -1.30; -1.80 Score on a scale

Primary: Change From Baseline in Choice Reaction Time (CRT) at 6 Weeks — 20.7; 21.9 msec — p=0.844

Primary: Remission of Depression (%) — 61.5; 33.3 percent of participants — p=.13

Primary: Mean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3 — 0.92; 0.92; 0.92; 0.96 mRNA relative values (ratio with GAPDH) — p=<0.001

Primary: Overall Response Rate, as Determined by Radiologic Evaluation (Utilizing the World Health Organization [WHO] Criteria), Calculated as the Number of Participants With the…